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After 12 frustrating and frightening months, 
the Chans finally received a diagnosis of 
Niemann-Pick type C disease (NPC), a 
rare, incurable childhood disease caused by 
the accumulation of excessive amounts of 
cholesterol and glycosphingolipids in the 
brain and other organs. Without FDA-
approved treatments, and with only drugs to 
manage symptoms, young people with the 
degenerative condition often die before the 
age of 20.  
“NPC is so rare that in all of Los Angeles, 
where we live, there are only four known 
cases,” says Brian Chan, Galya’s dad. “I’ve 
spent hundreds of hours researching it and 
talking to other families. As most NPC 
families do, I eventually ran into Dr. Vite at 
Penn Vet.”  
Dr. Charles H. Vite, Associate Professor 
of Veterinary Neurology, is part of a 
collaborative community of researchers 
around the world who are tackling NPC. 
Recently, he was the lead author of a 
study published in Science Translational 
Medicine that finds cats with NPC show vast 
improvement when treated with a compound 
called cyclodextrin. While NPC, which 
naturally occurs in cats and follows the same 
progression as it does in children, typically 
results in inexorable neurological decline, 
administering cyclodextrin into the fluid 
around the cats’ brains largely halted the 
disease’s progression. This study paved the 
way for the FDA to approve a Phase I clinical 
trial in children. A Phase 2/3 trial began this 
past fall.   
For the Chans and other parents of 
children with NPC, breakthroughs like 
this offer hope. Determined to maintain 
forward momentum, they have become 
FATHER’S GIFT TO VITE 
LAB IS PERSONAL
BY SACHA ADORNO
SOON AFTER GALYA CHAN WAS BORN, HER LIVER BEGAN 
GROWING AT AN ALARMING RATE—SO QUICKLY THAT BY THE 
TIME SHE TURNED ONE, IT WAS THE SIZE OF A 13-YEAR-OLD’S. 
WITH DOCTORS UNABLE TO IDENTIFY THE CAUSE, GALYA SPENT 
THE BETTER PART OF HER FIRST YEAR IN AN INTENSIVE CARE UNIT. 
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“We are grateful to 
Brian for this gift, 
and thankful for all 
of the determined, 
amazing families 
behind NPC research.” 
—Dr.CharlesH.Vite
active participants in NPC research, getting 
to know scientists and raising funds to keep 
studies moving.  
Brian Chan is the founder of Liferay, Inc., 
an open source software company, and part 
of SOAR-NPC (Support of Accelerated 
Research for NPC), a scientist-clinician-
patient advocate collaborative. After visiting 
Dr. Vite’s lab with a group of parents, Chan 
asked what was needed to accelerate research. 
“A new microscope was high on the list,” 
Chan says. 
Without hesitation, he offered to support 
the purchase of a state-of-the-art microscope 
that will greatly enhance Penn Vet’s ability 
to study NPC. Features like whole-slide 
scanning and 3-D reconstruction; digital 
archiving and sharing functions; high-
resolution and live-cell, real-time imaging; 
and multiplexing capabilities will enable a 
better understanding of NPC’s process. As 
a result, researchers can spend more time 
analyzing data and less time imaging it.
“We are grateful to Brian for this gift, and 
thankful for all of the determined, amazing 
families behind NPC research,” says Vite. 
“They alone have helped fund 20 percent of 
our lab. We have essential NIH funding—we 
couldn’t get by without it—but what really 
pushes things along is the involvement of the 
parents.” 
Regarding this unique partnership between 
families and researchers, Chan adds, “Doctors 
and scientists take an academic approach. For 
parents, it’s personal. If you add a personal 
touch to scientific rigor, the results are 
better than if you have just academic data or 
parental passion. When you combine both…
bam, things happen.” 
xxx
